Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

West syndrome: individualized ACTH therapy

H Heiskala1, R Riikonen, P Santavuori

  • 1Children's Hospital, University of Helsinki, Finland.

Brain & Development
|November 1, 1996
PubMed
Summary

Individualized adrenocorticotropic hormone (ACTH) treatment for West syndrome (WS) showed effectiveness. Tailoring ACTH dosage minimized side effects while managing infantile spasms in infants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood.

Journal of clinical immunology·2013
Same author

TSGA10 - A target for autoantibodies in autoimmune polyendocrine syndrome type 1 and systemic lupus erythematosus.

Scandinavian journal of immunology·2011
Same author

Risk of autoimmune diabetes in APECED: association with short alleles of the 5'insulin VNTR.

Genes and immunity·2010
Same author

Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)--a diagnostic and therapeutic challenge.

Pediatric endocrinology reviews : PER·2010
Same author

Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I.

Journal of internal medicine·2009
Same author

Brain magnetic resonance imaging of siblings from families with two or more children with learning or intellectual disabilities and need for full-time special education.

Acta radiologica (Stockholm, Sweden : 1987)·2009

Area of Science:

  • Pediatric Neurology
  • Endocrinology
  • Clinical Pharmacology

Background:

  • West syndrome (WS), characterized by infantile spasms, requires effective treatment strategies.
  • Adrenocorticotropic hormone (ACTH) is a recognized therapy for WS, but optimal dosing remains a focus.
  • Previous studies highlight variability in ACTH response and potential for dose-related adverse events.

Purpose of the Study:

  • To evaluate the efficacy and safety of individualized, stepwise-dosed ACTH treatment for West syndrome.
  • To determine optimal ACTH dosages for both cryptogenic and symptomatic infantile spasms.
  • To correlate ACTH dosage with treatment response and occurrence of adverse events.

Main Methods:

  • Prospective multicenter study involving 30 patients with infantile spasms (6 cryptogenic, 24 symptomatic).

Related Experiment Videos

  • Stepwise dose escalation of ACTH based on individual patient response.
  • Monitoring for seizure cessation, developmental outcomes, and adverse events (hypertension, cardiac hypertrophy, etc.).

    • Main Results:

    • In cryptogenic WS, 4/6 patients responded to low-dose ACTH (3 i.u./kg daily) with good outcomes.
    • In symptomatic WS, 21/24 patients required higher doses (6-12 i.u./kg daily), with 12 achieving seizure freedom or infrequent non-infantile spasms.
    • Adverse events including hypertension and cardiac hypertrophy were dose-dependent.

    Conclusions:

    • Individualized ACTH dosing in West syndrome offers therapeutic benefits with potentially reduced side effects and costs.
    • Tailored ACTH regimens can effectively manage infantile spasms in both cryptogenic and symptomatic cases.
    • Careful dose titration is crucial to balance efficacy and minimize adverse events in ACTH therapy for WS.